Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

In December, Novo Nordisk reported that CagriSema was able to muster a 22.7% weight loss at 68 weeks in REDEFINE 1, which also fell short of its hoped-for reduction of 25%.

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine ...

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

CagriSema, an investigational weight loss medicine, performed well in phase 3 studies, but not quite as well as management had promised. Elsewhere, Novo Nordisk's biggest rival in this area, Eli Lilly ...

So could you add weight to your portfolio by taking a slice of Eli Lilly, the US maker of Mounjaro, which is now being ...